So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel ...

A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests ...

Health Secretary Robert F. Kennedy Jr.'s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding ...

Pfizer recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for vepdegestrant, ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

Pima County health officials say fall vaccine supplies remain steady despite changes in federal research funding.